دورية أكاديمية
أعرض في EDS

Doxycycline vs Hydroxychloroquine + Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa (DOXYCOV).

التفاصيل البيبلوغرافية
العنوان: Doxycycline vs Hydroxychloroquine + Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa (DOXYCOV).
المؤلفون: Sobngwi E; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR.; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, CMR.; Research, RSD (Research Science and Development) Institute, Yaoundé, CMR.; The Biotechnology Center, University of Yaoundé 1, Yaoundé, CMR., Zemsi S; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR.; Research, RSD (Research Science and Development) Institute, Yaoundé, CMR., Guewo M; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, CMR.; Research, RSD (Research Science and Development) Institute, Yaoundé, CMR.; The Biotechnology Center, University of Yaoundé 1, Yaoundé, CMR., Katte JC; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaounde, CMR.; Research, RSD (Research Science and Development) Institute, Yaoundé, CMR., Kouanfack C; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR.; Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, CMR., Mfeukeu L; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR.; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, CMR., Zemsi A; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR., Wasnyo Y; Internal Medicine, Yaoundé Central Hospital, Yaounde, CMR.; Research, RSD (Research Science and Development) Institute, Yaoundé, CMR., Ntsama Assiga A; Internal Medicine, Yaoundé Central Hosptial, Yaounde, CMR., Ndi Manga A; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR.; Research and Development, RSD (Research Science and Development) Institute, Yaoundé, CMR., Sobngwi-Tambekou J; Research, RSD (Research Science and Development) Institute, Yaoundé, CMR., Ngatchou W; Hypertension Clinic, Erasme University Hospital, Brussels, BEL., Moussi Omgba C; Regional Delegation of Public Health, Ministry of Public Health, Yaoundé, CMR., Mbanya JC; Internal Medicine, Yaoundé Central Hospital, Yaounde, CMR.; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, CMR.; The Biotechnology Center, University of Yaoundé 1, Yaoundé, CMR., Ongolo Zogo P; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR.; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, CMR.; Center for the Development of Good Practices in Health, Yaoundé Central Hospital, Yaoundé, CMR., Fouda PJ; Internal Medicine, Yaoundé Central Hospital, Yaoundé, CMR.; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, CMR.
المصدر: Cureus [Cureus] 2023 Sep 20; Vol. 15 (9), pp. e45619. Date of Electronic Publication: 2023 Sep 20 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Objective We aimed to compare the safety and efficacy of a doxycycline-based regimen against Cameroon National Standard Guidelines (hydroxychloroquine plus azithromycin) for the treatment of mild symptomatic COVID-19. Methods We conducted an open-label, randomized, non-inferiority trial in Cameroon comparing doxycycline 100 mg, twice daily for seven days versus hydroxychloroquine 400 mg daily for five days and azithromycin 500 mg at day 1 and 250 mg from day 2 through 5 in mild COVID-19 patients. Clinical recovery, biological parameters, and adverse events were assessed. The primary outcome was the proportion of clinical recovery on days 3, 10, and 30. Non-inferiority was determined by the clinical recovery rate between protocols with a 20-percentage points margin. Results One hundred and ninety-four participants underwent randomization and were treated either with doxycycline (n = 97) or hydroxychloroquine-azithromycin (n = 97). On day 3, 74/92 (80.4%) participants on doxycycline versus 77/95 (81.1%) on hydroxychloroquine-azithromycin-based protocols were asymptomatic (p = 0.91). On day 10, 88/92 (95.7%) participants on doxycycline versus 93/95 (97.9%) on hydroxychloroquine-azithromycin were asymptomatic (p = 0.44). On day 30, all participants were asymptomatic. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) polymerase chain reaction (PCR) test was negative on day 10 in 60/92 (65.2%) participants who were assigned to doxycycline and in 63/95 (66.3%) participants who were assigned to hydroxychloroquine-azithromycin. None of the participants were admitted for worsening of the disease after treatment initiation. Conclusion Doxycycline 100 mg twice daily for seven days proved to be safe and non-inferior in terms of efficacy when compared to hydroxychloroquine-azithromycin for preventing clinical worsening of mild symptomatic or asymptomatic COVID-19 and achieving virological suppression.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Sobngwi et al.)
References: IDCases. 2020 Jun 06;21:e00864. (PMID: 32566483)
Am J Trop Med Hyg. 2020 Jun;102(6):1184-1188. (PMID: 32323646)
Drugs. 1992 Aug;44(2):207-15. (PMID: 1382015)
Arch Virol. 2014 Apr;159(4):711-8. (PMID: 24142271)
Wounds. 2012 Dec;24(12):339-49. (PMID: 25876218)
Allergy. 2021 Feb;76(2):533-550. (PMID: 32662525)
Eur J Pharmacol. 2021 Mar 15;895:173890. (PMID: 33482181)
Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204)
Ann N Y Acad Sci. 2011 Dec;1241:17-32. (PMID: 22191524)
Ann Intern Med. 2020 Oct 20;173(8):623-631. (PMID: 32673060)
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041. (PMID: 32936252)
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1800-1808. (PMID: 28516469)
Cureus. 2020 Aug 11;12(8):e9658. (PMID: 32802622)
Am J Trop Med Hyg. 2020 Jun;102(6):1154-1155. (PMID: 32297590)
Med Mal Infect. 2020 Jun;50(4):384. (PMID: 32240719)
Trials. 2020 May 24;21(1):422. (PMID: 32448345)
فهرسة مساهمة: Keywords: azithromycin; doxycycline; hydroxychloroquine; mild covid-19; sub-saharan africa
تواريخ الأحداث: Date Created: 20231023 Latest Revision: 20231030
رمز التحديث: 20231031
مُعرف محوري في PubMed: PMC10588815
DOI: 10.7759/cureus.45619
PMID: 37868535
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.45619